Difficulty: Medium
Average Score: 71%
Practice
Your patient with relapsed high-risk neuroblastoma returns to your care after travelling to an outside institution for 131I-MIBG therapy. In the weeks following 131I-MIBG therapy, what adverse events directly attributable to this therapy will the patient most likely encounter?
Correct answer
A
Rationale
The need for blood product support (both packed red blood cells [PRBC] and platelets) and growth factor support in the weeks following 131I-MIBG therapy is very common and expected. Many heavily pretreated patients require autologous stem cell infusion following 131I-MIBG therapy. Severe mucositis and hemorrhagic cystitis are not commonly associated with 131I-MIBG therapy. Although renal failure could be attributed to 131I-MIBG therapy, it is rare. Hypothyroidism is a very common finding but typically does not occur acutely. Evidence of effects on the thyroid is often based on laboratory studies, and many patients are asymptomatic.